Dong-A ST Co., Ltd. (KRX:170900)
South Korea
· Delayed Price · Currency is KRW 56,000
0.00 (0.00%)
At close: Dec 5, 2025
Dong-A ST Revenue
Dong-A ST had revenue of 215.93B KRW in the quarter ending September 30, 2025, with 12.76% growth. This brings the company's revenue in the last twelve months to 770.63B, up 10.04% year-over-year. In the year 2024, Dong-A ST had annual revenue of 697.87B with 5.10% growth.
Revenue (ttm)
770.63B
Revenue Growth
+10.04%
P/S Ratio
0.67
Revenue / Employee
458.98M
Employees
1,679
Market Cap
512.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 697.87B | 33.89B | 5.10% |
| Dec 31, 2023 | 663.98B | 28.59B | 4.50% |
| Dec 31, 2022 | 635.39B | 42.16B | 7.11% |
| Dec 31, 2021 | 593.23B | 6.50B | 1.11% |
| Dec 31, 2020 | 586.73B | -25.58B | -4.18% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |
Dong-A ST News
- 1 year ago - Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA - Financial Post
- 1 year ago - US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Financial Post
- 1 year ago - US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Benzinga